New FDA Approved Labeling for Sodium Hyaluronate (Hyalgan®)
Hyalgan® is most efficacious in patients with mild to moderate osteoarthritis (OA) of the knee. Recent data on controlled clinical trials (Am J Orthop 28:5-7, 1999) suggest that Hyalgan is effective at significantly relieving the pain of OA of the knee even at 12 months following one course of five intra-articular injections at weekly intervals. Additionally, in a 30-month safety study in 75 patients who received 5 courses of Hyalgan therapy over a 2-year period (Eur J Rheumatol Inflamm 15:57-62, 1995), no serious local or systemic side effects were noted. These data support the use of Hyalgan® in the long-term management of OA of the knee.
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.